ArticleMetabolomics : Official journal of the Metabolomic Society2026
Metabolomic and lipidomic plasma profiles according to metabolic dysfunction-associated steatotic liver diseases (MASLD) stages in the absence of type 2 diabetes (T2D).
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAmino acids (AAs), tricarboxylic acid (TCA) cycle intermediates, and acylcarnitines (ACs) can reflect energetic metabolism. Metabolic dysfunction-associated steatotic liver (MASLD) has been associated with the modification of plasma AAs, ACs and TCA cycle intermediates' profiles, but the changes in advanced fibrosis without type 2 diabetes (T2D) are not well studied.
objectivesThe objective of this pilot study was to describe the targeted plasma metabolomic profile in individuals with advanced fibrosis to test research hypotheses concerning hepatic energy metabolism.
methodsWe compared plasma fasting concentrations of 21 AAs, 11 organic acids (including ketone bodies and TCA cycle intermediates) and 14 ACs between individuals with advanced fibrosis stages (F3-F4/4) (n = 10) and individuals with no advanced fibrosis (n = 10), all without T2D and with similar clinical characteristics.
resultsMedian age (IQR) (51 [43-67] vs. 57 [43-66] years), sex (30 vs. 50% men) and BMI (35 [28-37] vs. 37 [32-39] kg/m
conclusionOverall, our results suggest impaired AAs catabolism and mitochondrial dysfunction. While the limited sample size and study design preclude causal inferences, these findings highlight potential metabolic signatures of advanced fibrosis in MASLD. They also underscore the need for larger, longitudinal studies to clarify their origin, significance, and clinical implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.